BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Tobira Therapeutics Inc. 

214 Carnegie Center
Suite 306
Princeton  New Jersey  08540  U.S.A.
Phone: 609-897-1102 Fax: n/a


SEARCH JOBS










 Company News
South San Francisco's Tobira Therapeutics Inc. Wraps Up $15 Million Loan Agreement 7/1/2014 7:05:52 AM
Tobira Therapeutics Inc. Adds To Its Board Of Directors 6/23/2014 8:15:16 AM
Tobira Therapeutics Inc. Appoints Chairman Laurent Fischer, MD, Chief Executive Officer And Christopher Peetz Chief Financial Officer 3/26/2014 1:20:31 PM
Tobira Therapeutics Inc. Presents Data Supporting Anti-Fibrotic Activity of Cenicriviroc in Liver Disease Models at The Liver Meeting 2013 11/4/2013 6:43:07 AM
Tobira Therapeutics Inc. Presents Positive 48-Week Data From Phase 2b Trial of Cenicriviroc in Treatment-Naïve HIV Infection at the 14th European AIDS Conference 10/17/2013 7:08:04 AM
Tobira Therapeutics Inc. Announces Publication of Cenicriviroc Formulation Improvement Providing Platform for Single Tablet and Fixed-Dose Combinations 10/4/2013 9:54:09 AM
Tobira Therapeutics Inc. Presents Positive Phase 2b Clinical Results for Cenicriviroc in Treatment-Naïve HIV Infection in Late Breaker Session at CROI 3/5/2013 1:49:37 PM
Tobira Therapeutics Inc. Announces Positive 24-Week Primary Analysis From Phase 2b Trial of Cenicriviroc in Treatment-Naïve HIV Infection 1/7/2013 10:30:05 AM
Tobira Therapeutics Inc. to Present at the 31st Annual J. P. Morgan Healthcare Conference 12/19/2012 7:12:07 AM
Tobira Therapeutics Inc. Receives Additional US Patent on Cenicriviroc 10/26/2012 7:37:09 AM
1234